The development of non-hormonal contraceptives is critical to increase options for women. In combination with prevention against sexually transmitted infections, they can become an important component of multipurpose prevention technologies (MPTs) which address multiple reproductive health needs with a single product. Resulting from multiple rounds of expert consultations, this framework aims to guide the development of non-hormonal contraceptive MPTs. Key informant interviews with experts in family planning and HIV and STI prevention and MPT product developers and funders from around the globe were conducted, reviewed, and coded. Identified key themes were discussed by experts at the November 2019 Eunice Kennedy Shriver National Institute of Child Health and Human Development Contraceptive Development Meeting in Houston, Texas. Seven action strategies were identified to address key research gaps and priorities for advancing the field. They highlight the importance of identifying target populations, a systematic approach to collaborative research, and leveraging knowledge from other fields, including regulatory and patenting, manufacturing, and commercialization expertise. Employing expanded target product profiles and setting go/no-go decisions for non-hormonal MPTs will help to prioritize the most promising candidates in the drug development pipeline. Further, they call for optimizing investments and engagement of stakeholders from public and private sectors. These action strategies aim to facilitate collaboration and innovation amongst multidisciplinary MPT stakeholders. Paramount to success will be enhancing strategic alliances and reconciling the essential social–behavioral context and market forces that drive product use with the complexities of research and development, regulatory approval, and commercialization.

中文翻译：

---

迈向推进非激素避孕多用途预防技术的路线图：来自主要利益相关者的战略见解†。

非激素避孕药的开发对于增加女性的选择至关重要。与性传播感染的预防相结合，它们可以成为多用途预防技术 (MPT) 的重要组成部分，通过单一产品满足多种生殖健康需求。该框架是多轮专家咨询的结果，旨在指导非激素避孕 MPT 的开发。对来自世界各地的计划生育和 HIV 和 STI 预防专家以及 MPT 产品开发者和资助者的主要知情人进行了访谈，并对其进行了审查和编码。专家在 2019 年 11 月Eunice Kennedy Shriver 上讨论了确定的关键主题国家儿童健康与人类发展研究所在德克萨斯州休斯顿举行的避孕发展会议。确定了七项行动战略，以解决关键研究差距和推进该领域的优先事项。他们强调了确定目标人群、协作研究的系统方法以及利用其他领域的知识（包括监管和专利、制造和商业化专业知识）的重要性。采用扩展的目标产品配置文件并为非激素 MPT 设置通过/不通过决策将有助于优先考虑药物开发管道中最有希望的候选药物。此外，他们呼吁优化公共和私营部门利益相关者的投资和参与。这些行动战略旨在促进多学科 MPT 利益相关者之间的合作和创新。成功的关键在于加强战略联盟并协调推动产品使用的基本社会行为环境和市场力量与研发、监管批准和商业化的复杂性。